| Literature DB >> 35169387 |
Matthias W Beckmann1, Frederik A Stübs1, Martin C Koch1, Peter Mallmann2, Christian Dannecker3, Anna Dietl1, Anna Sevnina1, Franziska Mergel1, Laura Lotz1, Carolin C Hack1, Anne Ehret4, Daniel Gantert4, Franca Martignoni4, Jan-Philipp Cieslik4, Jan Menke5, Olaf Ortmann6, Carmen Stromberger7, Karin Oechsle8, Beate Hornemann9, Friederike Mumm10, Christoph Grimm11, Alina Sturdza12, Edward Wight13, Kristina Loessl14, Michael Golatta15, Volker Hagen16, Timm Dauelsberg17, Ingo Diel18, Karsten Münstedt19, Eberhard Merz20, Dirk Vordermark21, Katja Lindel22, Christian Wittekind23, Volkmar Küppers24, Ralph Lellé25, Klaus Neis26, Henrik Griesser27, Birgit Pöschel28, Manfred Steiner29, Ulrich Freitag30, Tobias Gilster31, Alexander Schmittel32, Michael Friedrich33, Heidemarie Haase34, Marion Gebhardt34, Ludwig Kiesel25, Michael Reinhardt35, Michael Kreißl36, Marianne Kloke37, Lars-Christian Horn23, Regina Wiedemann38, Simone Marnitz39, Anne Letsch40, Isabella Zraik41, Bernhard Mangold42, Jochen Möckel43, Céline Alt44, Pauline Wimberger45, Peter Hillemanns46, Kerstin Paradies47, Alexander Mustea48, Dominik Denschlag49, Ulla Henscher50, Reina Tholen50, Simone Wesselmann51, Tanja Fehm4.
Abstract
Aim This update of the interdisciplinary S3 guideline on the Diagnosis, Therapy and Follow-up of Cervical Cancer (AWMF Registry No. 032/033OL) was published in March 2021. This updated guideline was funded by German Cancer Aid (Deutsche Krebshilfe) as part of the German Guideline Program in Oncology. The guideline was coordinated by the German Society of Gynecology and Obstetrics ( Deutsche Gesellschaft für Gynäkologie und Geburtshilfe , DGGG) and the Working Group on Gynecological Oncology ( Arbeitsgemeinschaft Gynäkologische Onkologie , AGO) of the German Cancer Society ( Deutsche Krebsgesellschaft , DKG). Method The process of updating the S3 guideline dating from 2014 was based on an appraisal of the available evidence using the criteria of evidence-based medicine, adaptations of existing evidence-based national and international guidelines or - if evidence was lacking - on a consensus of the specialists involved in compiling the update. After an initial review of the current literature was carried out according to a prescribed algorithm, several areas were identified which, in contrast to the predecessor version from September 2014, required new recommendations or statements which took account of more recently published literature and the appraisal of the new evidence. Recommendations The short version of this guideline consists of recommendations and statements on the epidemiology, screening, diagnostic workup and therapy of patients with cervical cancer. The most important new aspects included in this updated guideline include the newly published FIGO classification of 2018, the radical open surgery approach for cervical cancers up to FIGO stage IB1, and use of the sentinel lymph node technique for tumors ≤ 2 cm. Other changes include the use of PET-CT, new options in radiotherapy (e.g., intensity-modulated radiotherapy, image-guided adaptive brachytherapy), and drug therapies to treat recurrence or metastasis. Thieme. All rights reserved.Entities:
Keywords: cervical cancer; cervical intraepithelial neoplasia; follow-up; guideline; therapy
Year: 2022 PMID: 35169387 PMCID: PMC8837407 DOI: 10.1055/a-1671-2158
Source DB: PubMed Journal: Geburtshilfe Frauenheilkd ISSN: 0016-5751 Impact factor: 2.915